High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: Strategic flexibility explains potency against resistance mutations

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 5, 2008, Pages 1466-1471

  Das, Kalyan ^a,b   Bauman, Joseph D ^a,b   Clark Jr , Arthur D ^a,b   Frenkel, Yulia V ^a,b   Lewi, Paul J ^c   Shatkin, Aaron J ^a   Hughes, Stephen H ^d   Arnold, Eddy ^a,b  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Drug design; Drug resistance; Nonnucleoside reverse transcriptase inhibitor; Polymerase; X ray crystallography

Indexed keywords

DAPIVIRINE; DELAVIRDINE; EFAVIRENZ; ETRAVIRINE; NEVIRAPINE; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ENZYME INHIBITOR; NITRILE; PYRIMIDINE DERIVATIVE; REVERSE TRANSCRIPTASE, HUMAN IMMUNODEFICIENCY VIRUS 1; UNCLASSIFIED DRUG;

ARTICLE; COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG CONFORMATION; DRUG POTENCY; ENZYME STRUCTURE; GENE MUTATION; GENETIC RESISTANCE; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROPHOBICITY; INFECTION RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN MOTIF; REACTION OPTIMIZATION; VIRUS INHIBITION; WILD TYPE; AMINO ACID SEQUENCE; ANTIVIRAL RESISTANCE; CHEMISTRY; DRUG DESIGN; GENETICS; HUMAN; MOLECULAR GENETICS; MUTATION; PROTEIN CONFORMATION; PROTEIN ENGINEERING; X RAY CRYSTALLOGRAPHY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANTI-HIV AGENTS; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; HIV REVERSE TRANSCRIPTASE; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; NITRILES; PROTEIN CONFORMATION; PROTEIN ENGINEERING; PYRIMIDINES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 40349091258     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0711209105     Document Type: Article

References (28)

1. Ludovici DW, et al. (2001) Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues. Bioorg Med Chem Lett 11:2235-2239.
2. Guillemont J, et al. (2005) Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1. J Med Chem 48:2072-2079.
3. Janssen PA, et al. (2005) In search of a novel anti-HIV drug: Multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2- cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl] amino]benzonitrile (R278474, rilpivirine). J Med Chem 48:1901-1909.
4. Das K, Lewi PJ, Hughes SH, Arnold E (2005) Crystallography and the design of anti-AIDS drugs: Conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors. Prog Biophys Mol Biol 88:209-231.
5. Goebel F, et al. (2006) Short-term antiviral activity of TMC278-A novel NNRTI-in treatment-naive HIV-1-infected subjects. AIDS 20:1721-1726.
6. Pozniak A, et al. (2007) 48-week primary analysis of trial TMC278-C204: TMC278 demonstrates potent and sustained efficacy in ARV-naïve patients. 14th Conference on Retroviruses and Opportunistic Infections (CROI), February 25-28, 2007, Los Angeles, CA, paper 144LB.
7. Das K, et al. (2004) Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 47:2550-2560.
8. Pauwels R (2006) Aspects of successful drug discovery and development. Antiviral Res 71:77-89.
9. Frank KB, Noll GJ, Connell EV, Sim IS (1990) Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 343:470-474.
10. Lewi PJ, et al. (2003) On the detection of multiple-binding modes of ligands to proteins, from biological, structural, and modeling data. J Comput Aided Mol Des 17:129-134.
11. Clark ADJ, Jacobo-Molina A, Clark P, Hughes SH, Arnold E (1995) Crystallization of human immunodeficiency virus type 1 reverse transcriptase with and without nucleic acid substrates, inhibitors and an antibody Fab fragment. Methods Enzymol 262:171-185.
12. Rodgers DW, et al. (1995) The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. Proc Natl Acad Sci USA 92:1222-1226.
13. Hsiou Y, et al. (1996) Structure of unliganded HIV-1 reverse transcriptase at 2.7 Å resolution: Implications of conformational changes for polymerization and inhibition mechanisms. Structure (London) 4:853-860.
14. Ren J, et al. (1995) High-resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat Struct Biol 2:293-302.
15. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA (1992) Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256:1783-1790.
16. Lindberg J, et al. (2002) Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant. Eur J Biochem 269:1670-1677.
17. Himmel DM, et al. (2005) Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: A new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains. J Med Chem 48:7582-7591.
18. Ren J, et al. (2007) Relationship of potency and resilience to drug resistant mutations for GW420867X revealed by crystal structures of inhibitor complexes for wild-type, Leu100Ile, Lys101Glu, and Tyr188Cys mutant HIV-1 reverse transcriptases. J Med Chem 50:2301-2309.
19. Das K, et al. (2007) Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097. J Mol Biol 365:77-89.
20. Ren J, et al. (2004) Crystal structures of HIV-1 reverse transcriptases mutated at codons 100, 106 and 108 and mechanisms of resistance to non-nucleoside inhibitors. J Mol Biol 336:569-578.
21. Fang C, et al. (2008) Two dimensional infrared spectra reveal relaxation of the nonnucleoside inhibitor TMC278 complexed with HIV-1 reverse transcriptase. Proc Natl Acad Sci USA 105:1472-1477.
22. Nanni RG, Ding J, Jacobo-Molina A, Hughes SH, Arnold E (1993) Review of HIV-1 reverse transcriptase three-dimensional structure: Implications for drug design. Perspect Drug Disc Design 1:129-150.
23. Spence RA, Kati WM, Anderson KS, Johnson KA (1995) Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 267:988-993.
24. Otwinowski Z, Minor W (2001) DENZO and SCALEPACK (Kluwer, Boston).
25. Emsley P, Cowtan K (2004) Coot: Model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60:2126-2132.
26. Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53:240-255.
27. Brunger AT, Adams PD, Rice LM (1998) Recent developments for the efficient crystallographic refinement of macromolecular structures. Curr Opin Struct Biol 8:606-611.
28. Heeres J, Lewi PJ (2007) The medicinal chemistry of the DATA and DAPY series of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs). Advances in Antiviral Drug Design, ed De Clercq E (Elsevier, Amsterdam), Vol 5, pp 213-242.